Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

154.81 +0.29 (+0.19%)
Streaming Delayed Price Updated: 9:30 AM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Evaluating Johnson &amp; Johnson Against Peers In Pharmaceuticals Industry
Via Benzinga
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price. 
Via InvestorPlace
FDA Approves Johnson & Johnson's Reduced Tecvayli Dosing In Pretreated Multiple Myeloma Patients
FDA greenlights Johnson & Johnson's Tecvayli for reduced dosing in multiple myeloma patients, achieving complete response for 6+ months. 
Via Benzinga
Exposures Product Safety
2 Beaten-Down Stocks to Buy and Hold for 10 Years
One is a longtime healthcare leader, the other a newcomer; both have bright futures despite recent obstacles. 
Via The Motley Fool
Is NYSE:JNJ suited for dividend investing?
Balancing Dividends and Fundamentals: The Case of JOHNSON & JOHNSON (NYSE:JNJ). 
Via Chartmill
Top 7 Contenders to Join the Trillion-Dollar Club
Microsoft's ascent to the $3 trillion mark highlights the growing influence of trillion-dollar companies in the stock market. 
Via InvestorPlace
Johnson & Johnson Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
What the Options Market Tells Us About Johnson & Johnson
Via Benzinga
Looking Into Johnson & Johnson's Recent Short Interest
Via Benzinga
5 Forever Dividend Stocks to Build Your Portfolio
These five stocks are high quality and reliable. 
Via The Motley Fool
Income Lover’s Paradise: 3 Dividend Stocks with Stellar Track Records
Over 60 years of annual dividend growth signals that these dividend stocks are quality companies with durable competitive advantages. 
Via InvestorPlace
The Smartest Dividend Stocks to Buy With $400 Right Now
These companies will build an ever-growing stream of passive income, one share at a time. 
Via The Motley Fool
Steady Eddies: 3 Blue-Chip Stocks to Buy for the Long Haul
AAPL, AB InBev, and Johnson & Johnson are some of the best blue-chip stocks to buy and hold to fortify your investment portfolio. 
Via InvestorPlace
If You Invested $10,000 in Johnson & Johnson Stock in 2004, This Is How Much You Would Have Today
Johnson & Johnson has been a stalwart in the healthcare industry for decades, but has it made for a good investment? 
Via The Motley Fool
3 Unstoppable Dividend Stocks That Could Pay You for Life
There are no certainties in life or on the stock market. These companies' dividends are about as close as we can get. 
Via The Motley Fool
The 3 Biotech Stocks That Could Make Your February Unforgettable
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. 
Via InvestorPlace
7 Small-Cap Stocks With Significant Upside Potential in 2024
Dive into small-cap stocks for a mix of stability & growth, wagering on potential leaders before the market catches on. 
Via InvestorPlace
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
7 Stable Dividend Stocks to Ease Lingering Market Jitters
Although the economic coast seems clear, those who are still unsure can trust in the reliability of stable dividend stocks to buy. 
Via InvestorPlace
3 Dow Stocks You Can Confidently Buy Now and Hold Forever
Three highly profitable, time-tested Dow components have the necessary tools to make their patient shareholders notably richer. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
A Look At Pharma ETFs After Q4 Earnings
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
From Johnson & Johnson
Via Business Wire
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
These incredible businesses have long histories of successes behind them, and more to come. 
Via The Motley Fool
Passive Income Powerhouses: 7 Blue-Chip Stocks to Own Now
If you are looking to build wealth through dividend income, here are the passive income blue-chip stocks to buy. 
Via InvestorPlace
DNA Sequencing Kit Provider Illumina's Q4 Earnings Edge Above Street Estimates, Works To Resolve GRAIL Quickly
Illumina exceeds Q4 2023 expectations with $1.12 billion sales, up 4% YoY. CEO Jacob Thaysen anticipates growth and outlines strategic priorities for 2024. 
Via Benzinga
Dividend Dynasties: 3 Stocks Set to Deliver Consistent Income
Unlock reliable cash flow with these Dividend Aristocrats. They're elite S&P 500 dividend stocks raising payouts for 25+ years. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
Via Benzinga
3 Dividend Stocks to Cling to This Year
Build a retirement portfolio with these three dividend stocks to enjoy passive income and capital growth over the years. 
Via InvestorPlace
Topics Retirement
Exposures Pension
The Watch List: Is Warren Buffett Still Selling These 3 Stocks?
Just because Warren Buffett marked these as stocks to sell doesn't always mean investors need to walk lockstep with him. 
Via InvestorPlace
Is Johnson & Johnson a Good Dividend Stock to Buy Now?
The healthcare conglomerate has been raising its dividend payout since Kennedy was president, but there have been some recent changes. 
Via The Motley Fool
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.